Plasticity of disseminating cancer cells in patients with epithelial malignancies.

The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med (2013) 3.96

Tumor metastasis: moving new biological insights into the clinic. Nat Med (2013) 2.71

Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell (2013) 2.08

Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat Nanotechnol (2013) 1.92

Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med (2014) 1.62

Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. Mol Cancer (2013) 1.27

Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease. Cell Death Dis (2013) 1.20

Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis. Front Oncol (2015) 1.15

Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. Oncotarget (2014) 1.08

Towards elucidating the connection between epithelial-mesenchymal transitions and stemness. J R Soc Interface (2014) 1.04

Tumor Budding: The Name is EMT. Partial EMT. J Clin Med (2016) 1.00

Emerging Biological Principles of Metastasis. Cell (2017) 0.94

The biological and clinical importance of epithelial-mesenchymal transition in circulating tumor cells. J Cancer Res Clin Oncol (2014) 0.94

Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. Br J Cancer (2013) 0.94

Seed, soil, and beyond: The basic biology of brain metastasis. Surg Neurol Int (2013) 0.92

Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer? Cancers (Basel) (2014) 0.92

Clinical implications of circulating tumor cells of breast cancer patients: role of epithelial-mesenchymal plasticity. Front Oncol (2015) 0.90

Pivotal role of pervasive neoplastic and stromal cells reprogramming in circulating tumor cells dissemination and metastatic colonization. Cancer Microenviron (2014) 0.90

Coupling the modules of EMT and stemness: A tunable 'stemness window' model. Oncotarget (2015) 0.86

Membrane Proteins Involved in Epithelial-Mesenchymal Transition and Tumor Invasion: Studies on TMPRSS4 and TM4SF5. Genomics Inform (2014) 0.85

TGF-β1-Induced Epithelial-Mesenchymal Transition Promotes Monocyte/Macrophage Properties in Breast Cancer Cells. Front Oncol (2015) 0.85

Detection and Clinical Significance of Circulating Tumor Cells in Colorectal Cancer-20 Years of Progress. Mol Med (2015) 0.83

Circulating tumor cells in breast cancer. J Carcinog (2014) 0.83

Circulating tumor cells in prostate cancer. Cancers (Basel) (2013) 0.83

Circulating cancer stem cells: the importance to select. Chin J Cancer Res (2015) 0.81

Characterization of different CTC subpopulations in non-small cell lung cancer. Sci Rep (2016) 0.81

Detection methods of circulating tumor cells. J Thorac Dis (2012) 0.80

Bardoxolone methyl induces apoptosis and autophagy and inhibits epithelial-to-mesenchymal transition and stemness in esophageal squamous cancer cells. Drug Des Devel Ther (2015) 0.79

Aspirin inhibit platelet-induced epithelial-to-mesenchymal transition of circulating tumor cells (Review). Biomed Rep (2014) 0.79

Cellular Plasticity in Prostate Cancer Bone Metastasis. Prostate Cancer (2015) 0.78

Epithelial-mesenchymal plasticity is a decisive feature for the metastatic outgrowth of disseminated WAP-T mouse mammary carcinoma cells. BMC Cancer (2015) 0.78

Homeostatic Signaling by Cell-Cell Junctions and Its Dysregulation during Cancer Progression. J Clin Med (2016) 0.77

Enrichment of circulating head and neck tumour cells using spiral microfluidic technology. Sci Rep (2017) 0.77

Evaluation of epithelial-mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: Relevance to therapy response. World J Gastroenterol (2015) 0.77

Approaches to isolation and molecular characterization of disseminated tumor cells. Oncotarget (2015) 0.76

The potential for liquid biopsies in the precision medical treatment of breast cancer. Cancer Biol Med (2016) 0.76

Epithelial-mesenchymal transition in prostate cancer is associated with quantifiable changes in nuclear structure. Prostate (2014) 0.75

A Versatile Microarray Platform for Capturing Rare Cells. Sci Rep (2015) 0.75

Interrelationships of circulating tumor cells with metastasis and thrombosis: role of microRNAs. Curr Pharm Des (2014) 0.75

Data-Driven Discovery of Extravasation Pathway in Circulating Tumor Cells. Sci Rep (2017) 0.75

Circulating tumor microemboli (CTM) and vimentin+ circulating tumor cells (CTCs) detected by a size-based platform predict worse prognosis in advanced colorectal cancer patients during chemotherapy. Cancer Cell Int (2017) 0.75

A New Cell Block Method for Multiple Immunohistochemical Analysis of Circulating Tumor Cells in Patients with Liver Cancer. Cancer Res Treat (2016) 0.75

Therapeutic Targeting of Epithelial Plasticity Programs: Focus on the Epithelial-Mesenchymal Transition. Cells Tissues Organs (2017) 0.75

Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells. Oncotarget (2016) 0.75

When Prostate Cancer Circulates in the Bloodstream. Diagnostics (Basel) (2015) 0.75

Characteristics of circulating tumor cells in organ metastases, prognosis, and T lymphocyte mediated immune response. Onco Targets Ther (2017) 0.75

Circulating Tumor Cells: Moving Biological Insights into Detection. Theranostics (2017) 0.75

Detection of disseminated tumor cells in aspirative drains after neck dissection. Eur Arch Otorhinolaryngol (2015) 0.75

Cell-surface major vault protein promotes cancer progression through harboring mesenchymal and intermediate circulating tumor cells in hepatocellular carcinomas. Sci Rep (2017) 0.75

A Novel Workflow to Enrich and Isolate Patient-Matched EpCAM(high) and EpCAM(low/negative) CTCs Enables the Comparative Characterization of the PIK3CA Status in Metastatic Breast Cancer. Int J Mol Sci (2017) 0.75

Biomarkers for early diagnosis, prognosis, prediction, and recurrence monitoring of non-small cell lung cancer. Onco Targets Ther (2017) 0.75

Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer. Transl Oncol (2017) 0.75

Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer (2011) 7.69

A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med (2005) 6.86

Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res (2007) 6.59

Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol (2013) 4.11

Circulating tumor cells: liquid biopsy of cancer. Clin Chem (2012) 3.87

Cancer micrometastases. Nat Rev Clin Oncol (2009) 3.69

VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell (2011) 3.23

Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res (2010) 2.98

The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer (2005) 2.74

Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer (2008) 2.72

Tumor metastasis: moving new biological insights into the clinic. Nat Med (2013) 2.71

Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res (2010) 2.66

Circulating epithelial cells in patients with benign colon diseases. Clin Chem (2011) 2.57

Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res (2013) 2.50

Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res (2005) 2.31

Circulating tumor cells and circulating tumor DNA. Annu Rev Med (2011) 2.16

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat (2010) 2.12

Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res (2005) 2.10

Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell (2013) 2.08

Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res (2008) 2.06

Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med (2010) 2.02

Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med (2012) 2.00

A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer (2006) 1.82

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev (2013) 1.82

Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res (2012) 1.79

Cancer micrometastasis and tumour dormancy. APMIS (2008) 1.78

ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res (2011) 1.75

High incidence of EMMPRIN expression in human tumors. Int J Cancer (2006) 1.74

Controversies in clinical cancer dormancy. Proc Natl Acad Sci U S A (2011) 1.71

Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res (2012) 1.63

Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell (2013) 1.62

Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst (2005) 1.60

Circulating tumor cell isolation and diagnostics: toward routine clinical use. Cancer Res (2011) 1.58

Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis. Clin Cancer Res (2011) 1.56

Biologic challenges in the detection of circulating tumor cells. Cancer Res (2012) 1.55

Real-time liquid biopsy in cancer patients: fact or fiction? Cancer Res (2013) 1.54

Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem (2012) 1.53

Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin Cancer Res (2003) 1.53

Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res (2006) 1.52

Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res (2003) 1.51

Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res (2009) 1.50

Tumor cell dormancy: an NCI workshop report. Cancer Biol Ther (2007) 1.50

Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization. Pathobiology (2008) 1.47

Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin Cancer Res (2004) 1.40

Clinical relevance and biology of circulating tumor cells. Breast Cancer Res (2011) 1.34

Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin Cancer Res (2004) 1.33

Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res (2004) 1.31

Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells. Clin Cancer Res (2012) 1.30

Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res (2013) 1.29

Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem (2007) 1.28

Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer (2013) 1.27

Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. Int J Cancer (2011) 1.27

High-resolution genomic profiling of occult micrometastatic tumor cells. Genes Chromosomes Cancer (2003) 1.25

Circulating tumors cells as biomarkers: progress toward biomarker qualification. Cancer J (2011) 1.25

Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res (2009) 1.25

Technologies for detection of circulating tumor cells: facts and vision. Lab Chip (2013) 1.24

Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer (2013) 1.23

Circulating tumor cells as therapy-related biomarkers in cancer patients. Cancer Immunol Immunother (2013) 1.23

Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU Int (2010) 1.22

Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol Oncol (2011) 1.21

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Res (2012) 1.21

Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Res (2012) 1.20

Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod Pathol (2013) 1.19

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood (2013) 1.19

Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. Clin Cancer Res (2009) 1.19

Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann N Y Acad Sci (2008) 1.17

Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol (2012) 1.16

Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res Treat (2012) 1.16

Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS One (2013) 1.16

Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells. Ann N Y Acad Sci (2010) 1.15

Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci U S A (2002) 1.15

The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate (2011) 1.13

Bi-specific immunomagnetic enrichment of micrometastatic tumour cell clusters from bone marrow of cancer patients. J Immunol Methods (2005) 1.13

Regulation of estrogen-dependent transcription by the LIM cofactors CLIM and RLIM in breast cancer. Cancer Res (2009) 1.12

Detection and measurement of occult disease for the prognosis of solid tumors. J Clin Oncol (2003) 1.11

The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat (2012) 1.11

L1 is associated with micrometastatic spread and poor outcome in colorectal cancer. Mod Pathol (2007) 1.10

Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin Chem (2013) 1.10

Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern. Breast Cancer Res Treat (2010) 1.09

Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem (2013) 1.09

Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance. Breast Cancer Res (2008) 1.09

Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Res Treat (2014) 1.08

Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells. Cell Signal (2011) 1.08

Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells. Int J Cancer (2003) 1.08

Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncol (2008) 1.07

Dual roles of the transcription factor grainyhead-like 2 (GRHL2) in breast cancer. J Biol Chem (2013) 1.07

Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer. Breast Cancer Res (2009) 1.06

Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors. PLoS One (2012) 1.06

Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer. Clin Cancer Res (2003) 1.05

Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters. Mol Cancer Res (2007) 1.05

Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) is associated with increased angiogenic potential in non-small-cell lung cancer. Lung Cancer (2008) 1.04

The clinical significance of circulating tumor cells. Nat Clin Pract Oncol (2007) 1.04

Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer. Anticancer Res (2006) 1.03

Tumour cells in the tumour draining vein of patients with non-small cell lung cancer: detection rate and clinical significance. Eur J Cardiothorac Surg (2003) 1.03

Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression. BMC Cancer (2011) 1.02